Protein kinase inhibitor as a potential candidate for epilepsy treatment by Gajda, Zita et al.
Protein kinase inhibitor as a potential candidate for epilepsy
treatment
*Zita Gajda, *Rita To¨ro¨k, yZolta´n Horva´th, yCsaba Sza´ntai-Kis, yzLa´szlo´ }Orfi, yxGyo¨rgy Ke´ri,
and *Magdolna Szente
*Department of Comparative Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary;
yVichem Chemie LTD, Budapest, Hungary; zDepartment of Pharmaceutical Chemistry, Semmelweis University,
Budapest, Hungary; and xPathobiochemistry Research Group of Hungarian Academy of Sciences,
Department of Medical Chemistry, Semmelweis University, Budapest, Hungary
SUMMARY
Purpose: Effects of the ‘‘VID-82925’’ kinase inhibitor mol-
ecule were investigated both during the developing phase
as well as during the stable phase of the focus with sponta-
neous recurrent seizures using the 4-AP-induced in vivo
epilepsy model in anesthetized rats.
Methods: In electrophysiologic experiments, VID-82925
(0.85 mg/kg) was injected intravenously either before the
induction (pretreatment) or after the development of the
stable focus (treatment). Reference drugs carbamazepine
(4.8 mg/kg) and levetiracetam (50 mg/kg) were employed
using the same experimental paradigm. The antiepileptic
effect of VID-82925 was also compared to those of the
broad-spectrum gap junction channel blocker carbenoxo-
lone (10 mM).
Key Findings: Pretreatment with VID-82925 revealed an
antiepileptogenic effect as it suppressed significantly the
manifestation of the epileptiform activity not only during
the developing phase, but also for a considerable long per-
iod during the stable phase of the focus. The current data
donotallow us todifferentiate anantiictal treatment effect
from an antiepileptogenic effect of the compound during
the stable phase of the focus. Treatment with VID-82925
was also effective against ictogenesis during the stable
phase of the focus. Pretreatment with levetiracetam failed
to exert any antiepileptogenic effect. The antiepileptic
effects of VID-82925 and of the reference drugs on the epi-
leptiform activity of the stable focus were comparable in
intensity; however, the effect of VID-82925 was 2–3 times
longer. The effects of VID-82925 and of carbenoxolone
overlapped one another to some extent, suggesting that
VID-82925 may exert its effects at least partially through
blocking of gap junctional communication.
Significance: Our results indicate that inhibition of pro-
tein kinases may also provide an effective strategy for the
development of a drug that is not only antiepileptic but
also depresses the course of epileptogenesis.
KEY WORDS: Antiepileptogenic, Antiepileptic, Kinase
inhibitor, In vivo.
According to the World Health Organization (WHO),
approximately 50 million people in the world have epi-
lepsy. The currently available antiepileptic drugs (AEDs)
although effective as suppressants of ictogenesis (i.e., mani-
festation and spread of seizures in the already epileptic brain
(Loscher & Schmidt, 2006), do not affect the development
of epilepsy (Dudek et al., 2008). In addition, despite
progress in understanding the pathogenesis of epilepsy,
seizures remain uncontrolled in at least 20–30% of patients.
In general, these drugs act either by the modulation of
voltage-gated ion channels or by enhancement of synaptic
inhibition mediated by c-aminobutyric acid (GABA)A
receptors or by inhibition of synaptic excitation mediated by
ionotropic glutamate receptors (Rogawski, 2006).
The significant number of patients with poorly controlled
seizures suggests that some clinically relevant proepileptic
mechanisms are not targeted by any of the currently avail-
able AEDs. The reason for this could be that most of the
AEDs were tested by using the same few classical epilepsy
models (Pitkanen et al., 2007; Smith et al., 2007; Dudek
et al., 2008), which mainly involve the similar actions,
without consideration of the variations in the pathophysio-
logic mechanisms that result in epilepsy. Therefore, to
search for possible new cellular and/or molecular targets in
combination with the use of new animal models may pro-
vide more successful strategies for the development of drugs
that might be effective for the currently drug-resistant epi-
lepsies, as well as for preventing epileptogenesis.
The nonsynaptic intercellular communication via gap
junction (GJ) channels both between inhibitory interneurons
and astrocytes have been shown recently to be an efficient
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synchronizing mechanism (Tamas et al., 2000; Giaume
et al., 2010) that contributes to the manifestation and propa-
gation of seizures and to the enhanced epileptogenicity of
the adult (Perez Velazquez & Carlen, 2000; Szente et al.,
2002; Gajda et al., 2003, 2005) and developing neocortex
(Gajda et al., 2006 and see for review Szente, 2008). Grow-
ing evidence demonstrates that protein phosphorylation by
various kinases are involved in the regulation of GJ commu-
nication (Cruciani & Mikalsen, 2002; Moreno & Lau, 2007;
Solan & Lampe, 2009).
Therefore, in a series of experiments, we tested the
effects of some kinase inhibitors on the semichronic 4-am-
inopyridine (4-AP)–induced in vivo epilepsy model both
during the epileptogenesis as well as during the stable
phase of the focus with spontaneous recurrent seizures.
Because the consecutive spontaneous seizures appear with
short interseizure intervals in this model, the possibility of
long seizure monitoring provide good opportunities to
carry out reliable quantitative measurements on the
effects of pharmacologic agents on the electrophysiologic
manifestation of seizures. In the present paper we draw
attention to the ‘‘VID-82925’’ marked molecule (provided
by Vichem Chemie Ltd, Budapest, Hungary), which turned
out to be one of the most efficient kinase inhibitors against
epileptiform activity.
In the 4-AP epilepsy model, two phases of the maturation
of the epileptic focus can be distinguished. The developing
phase of the focus takes approximately 50 € 10 min that
includes the latency period (usually 1–3 min), elapsing
between the application of the 4-AP and the appearance of
the first seizure (Fig. 2A, control in light shaded panel), and
the subsequent period when the frequency and the duration
of the seizures as well as the amplitudes of seizure dis-
charges increase gradually up to a stable level. During the
following stable phase of the epileptic focus, the parameters
of the epileptiform activity remain rather reliable for a con-
siderable time period (Fig. 2A, control in dark shaded
panel). Of course it is not possible to delineate exactly a
sharp border between the developing phase and the stabi-
lized phase of the focus. Since epileptogenesis is the gradual
process whereby normal brain is transformed into a state
susceptible to spontaneous, episodic, time-limited, recurrent
seizures through the initiation and maturation of an epilep-
togenic focus (Engel et al., 2008), in our experimental
circumstances, the developing phase of the focus might be
considered as epileptogenesis.
Our earlier observations (Szente et al., 2002; Gajda et al.,
2005, 2006) suggest that different cellular and network
mechanisms could be involved in the development of the
epileptic focus and in the maintenance of seizure activity of
an already stable epileptic focus. Therefore, in the present
study we aimed to investigate the effects of VID-82925 both
during the developing phase of the epileptic focus and dur-
ing the activity of the already stable epileptic focus. With
the intention of estimating the power of the effects of
VID-82925 on epileptiform activity, its data were compared
with those of the well-known and clinically widely used
AEDs (carbamazepine and levetiracetam) that were also
tested on the 4-AP epilepsy model in identical circum-
stances. Previous experiments in the kindling model
suggested that levetiracetam in addition to its seizure-
suppressing activity, may possess antiepileptogenic activity
(Lçscher et al., 1998). Attempting to check the possible
blocking effect of VID-82925 on GJal communication, we
tested by electrophysiologic technique whether the effects
of VID-82925 and of the broad-spectrum GJ blocker carbe-
noxolone overlap fully or partially with each other.
Methods
Experimental procedures
Acute electrophysiologic experiments were carried out
on adult (30–40-day-old) Wistar rats (body weight: 200–
300 g) of either gender (Charles River Laboratories,
Budapest, Hungary). All experimental procedures were
conducted in accordance with the United States Public
Health Service’s Guidelines for the Care and Use of Labo-
ratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of
Szeged.
Under transient diethyl ether narcosis, a metal cannula
was inserted into the tail marginal vein, and then the animals
were anesthetized intravenously (i.v.) with sodium pento-
barbital (50 mg/kg). The trachea was cannulated with a
polyethylene tube. The heads of the animals were secured in
a stereotaxic instrument. For recording of electrocortical
activity (ECoG), four holes (2–3 mm wide) were drilled in
the skull, and the dura mater was carefully removed at the
prospective site of the primary focus (Pf). Then animals
were left to rest for 30 min.
The seizure activity at the Pf was induced by the local
application of the potassium channel blocker 4-AP (on a
3 · 3 mm piece of filter paper soaked with saline) to the
somatosensory cortical surface (Szente & Baranyi, 1987;
Szente et al., 2002) in both female (n = 3) and male (n = 3)
rats. Because no significant differences were found in the
results of male and female rats, data were pooled together
for statistical analysis. Four silver ball electrodes connected
to an eight-channel electroencephalograph were used to
record ECoG from the Pf and mirror focus (Mf, the homo-
topic area contralateral to the Pf), as well as from two pos-
terior cortical points, in order to detect the manifestation
and propagation of epileptiform discharges. In parallel with
ECoGmonitoring, electrocardiography (ECG) was also per-
formed during the experiments to test the possible effect of
the tested drugs on the heart activity.
The general state of the animals (level of anaesthesia,
body temperature) was checked regularly throughout the
experiments. All efforts were made to minimize the num-
ber of animals used and their suffering. At the end of the
580
Z. Gajda et al.
Epilepsia, 52(3):579–588, 2011
doi: 10.1111/j.1528-1167.2011.02979.x
experiments, the animals were given a lethal dose of sodium
pentobarbital.
Tested drugs
VID-82925 (0.85 mg/kg) was dissolved in 0.9% saline
and sonicated for 45 min for complete dissolving. Carbe-
noxolone (10 mM; Sigma Aldrich, Budapest, Hungary)
was dissolved in 0.9% saline. Levetiracetam (Keppra,
50 mg/kg; provided by the Pharmacy of Faculty of Medi-
cine of University of Szeged) was in the form of concen-
trated solution and diluted with saline the day of the
experiments. For choosing the appropriate dose of leveti-
racetam for rats, we considered its dosage in the clinical
practice described in the literature. Levetiracetam is used
from 10 up to 40 mg/kg/day for children and from 1,000
up to 3,000 mg/day for adults (Toublanc et al., 2008). For
carbamazepine (4.8 mg/kg; Sigma Aldrich) first stock
solution was prepared in 100% DMSO (Sigma Aldrich)
and then diluted with saline to appropriate concentrations
for the individual experiments. Final DMSO concentration
was 1%. This concentration of DMSO has been shown to
have no effects on neuronal excitability (Mclean & Mac-
donald, 1986).
Drug testing protocols
Two experimental protocols were used in which all tested
drugs except carbenoxolone were administered intrave-
nously. The mechanisms of actions of the tested AEDs and
of pentobarbital are different (Schachter, 2007; Dudek
et al., 2008); however, their possible interaction cannot be
excluded. In any case, we paid attention that all of the tested
chemicals were investigated in identical experimental para-
digms. In the pretreatment experiments, we aimed to study
the effects of tested drugs on the development of the epilep-
tic focus, which means both the premanipulation of the cor-
tex by the tested drug before 4-AP application (Fig. 2A,
dotted panel), as well as the manipulation of the cortex dur-
ing the developing phase of the epileptic focus (Fig. 2A,
light shaded panel). In treatment experiments, we aimed to
study the effects of the tested drugs on the ictogenesis;
therefore, the drugs were applied during the stable phase of
the focus producing spontaneous recurrent seizures
(Fig. 2A, dark shaded panel).
Pretreatment
The rats were injected by VID-82925 (i.v.; n = 10) or by
levetiracetam (i.v.; n = 5), respectively, prior to the applica-
tion of 4-AP. The time between the application of the drugs
and the application of 4-AP (60 min in the case of VID-
82925 and 20 min in the case of levetiracetam) was chosen
according to the peak time of the drug’s effect (observed in
treatment experiments) to be sure that the drug was still
effective during the entire developing phase. Data were
recorded until the effects of the drug started to decline but at
least for 220 min after the application of 4-AP. The control
data were collected from a separate group of rats (n = 6)
submitted to an identical experimental paradigm, but pre-
treatment was carried out with saline instead of the drugs.
Treatment
The rats were treated by VID-82925 (iv; n = 10), by car-
bamazepine (i.v.; n = 6) or by levetiracetam (i.v.; n = 5), or
by carbenoxolone (locally by means of a 3 · 3 mm piece of
filter paper, soaked with carbenoxolone solution applied on
top of the filter paper containing 4-AP), respectively,
60 min after the application of 4-AP (35–40 seizures/
60 min). Data were collected until the effects of the drug
started to decline but at least for 260 min after the applica-
tion of the drug. In these experiments, the data collected
from the same animal for 20 min before the application of
the drug served as the control values.
Checking the possible blocking effect of VID-82925 on
GJal communication
In one series of experiments, after 35–40 spontaneously
repeated seizures, the Pf was first treated with carbenoxo-
lone; then before development of its peak effects (10 min
after the application of carbenoxolone), VID-82925 was
injected (n = 10). The data were then collected for an addi-
tional 250 min.
In the other series of experiments, after 35–40 spontane-
ously repeated seizures, the VID-82925 was injected first,
then before development of its maximum effects (100 min
after the administration of VID-82925), carbenoxolone was
applied (n = 10). The data were then collected for an addi-
tional 160 min.
Statistical analysis
In addition to ECoG paper recording, data were also
stored in a computer memory with the aid of Digidata
1200B, and analyzed by Mathcad (MathSoft, Cambridge,
MA, U.S.A.), Origin (OriginLab, Northampton, MA,
U.S.A.) processing software completed by a homemade
statistical program after the experiments. The effects of
the drugs on epileptiform activity were assessed by mea-
suring the latency of the first seizure (the time that
elapses between the application of 4-AP and the appear-
ance of the first seizure), the number and duration of sei-
zures as well as the amplitude of epileptiform discharges
of Pf. The summated ictal activity is a calculated parame-
ter and indicates the total duration of seizure activity dur-
ing a certain time window; therefore, it is useful for
evaluating the intensity of epileptiform activity. The sum-
mated ictal activity was determined by multiplying the
number of individual seizures by their durations measured
in 20 min time periods.
Results are given as means € SD. Student’s t-test was
used to assess significant differences between the control
and experimental groups of ECoG and ECG data. The level
of statistical significance was set at p < 0.05.
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Results
Depressing effect of VID-82925 on the development of
the epileptic focus
The VID-82925 did not noticeably influence the basic
electrocortical activity (Fig. 1A). Although the latency of
the first seizure (138 € 42 s) was in the same range in the
presence of VID-82925 as in controls (139 € 52 s), pre-
treatment with VID-82925 revealed a strong antiepilepto-
genic effect as suppressed significantly the manifestation of
the epileptiform activity not only during the developing
phase, but also for a considerably long period during the sta-
ble phase of the focus.
The number of seizures was only 65% of the control
value at the 20th min after the induction of epileptiform
activity, and then reached its lowest level (24.6% of the
control value) at the 120th min (Table 1). From here it
increased but was still only 63% of the control value at the
220th min. The durations of seizures were slightly shorter
than the controls values until the 80th min (Table 1). By
the 100th min it approached the control level. From here
seizures gradually became longer and the duration was
134% of the control value at the 220th min. Despite the
increase in seizure duration the overall effects of VID-
82925 are depressing because of the prominent decrease of
the number of seizures. The summated ictal activity was
only 55% of the control value at the 20th min; by the 40th
min reached its minimum (31% of the control value) and
then stayed persistently at considerably decreased level
until the 180th min (Fig. 2A). At the 200th min (260 min
after the administration of VID-82925) it gradually
approached the control level.
The amplitudes of seizure discharges were only 81% of
the control value at the 20th min and only 73% at the 80th
min (Table 1). From here the difference between the pre-
treated and control animals decreased, but the amplitudes
A
B
Figure 1.
Representative ECoG samples showing the effects of VID-82925 on the basic cortical electric activity (A) and on the manifestation of
individual seizures at the already active epileptic focus (B). The scheme illustrates the arrangement of the ECoG recording electrodes
and the sites of the primary focus (Pf) and mirror focus (Mf).
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were still only 83% of the control value at the 220th min in
pretreated animals.
Depressing effect of VID-82925 on the ictogenesis of the
already stable epileptic focus
The effects of VID-82925 on the ictogenesis of the
already stable epileptic focus turned out to be even more
remarkable than its effects on the development of the
focus. The decrease in the number of seizures first
became significant at the 40th min after the application of
VID-82925 (Table 2). The number of seizures reached its
lowest level (28% of control value) at the 180th min; it
then increased but was still significantly below the con-
trol level at the 260th. The decrease in the duration of
seizures first became significant at the 20th min
(Table 2). The durations were the shortest (57% of the
control value) at the 140th min, and then increased gradu-
ally and approached the control level at the 240th min,
and at the 260th min became 116% of the control value.
The over increase in the durations could be the indication
of a rebound (withdrawal) phenomenon after the decline
of the effects of VID-82925. It was rather imposing that
during the most effective phase of VID-82925, the dura-
tion of seizure-free periods was as long as 183.3 € 10 s
in comparison to the control value of 16.1 € 5 s
(Fig. 1B). In some VID-82925–treated animals even
10 min elapsed between the manifestations of succeeding
seizures. The decrease in the summated ictal activity first
became significant at the 20th min (Fig. 2B). Then sum-
mated ictal activity decreased further and reached its min-
imum at the 140th min (19% of the control value), and
stayed at considerably depressed level even until the
240th min, and was still only 67% of the control value at
the 260th min.
Despite the remarkable depressed epileptiform activity
under the influence of VID-82925, the amplitudes of seizure
discharges did not modify noticeably (Fig. 1B and Table 2).
Comparison between the efficiency of VID-82925 and
the reference AEDs
In levetiracetam pretreatment experiments, the epilepti-
form activity did not differ considerably from that of con-
trol (Fig. 2A). In contrary, pretreatment with VID-82925
exerts a clear depressing effect, indicated by a signifi-
cantly reduced epileptiform activity, measured during the
developing phase, but even at 180 min (see details ear-
lier).
In treatment experiments the antiepileptic effects of
VID-82925 and of the reference drugs on the epileptiform
activity of the stable focus were comparable in intensity;
however, the effect of VID-82925 was 2–3 times longer.
The carbamazepine decreased the summated ictal activity
down to one fifth of the control value at its peak effect, and
this activity lasted approximately as long as 80 min
(Fig. 2B). The levetiracetam decreased the summated ictal
activity slightly below one third of the control value, and
this activity lasted approximately as long as 100 min. The
VID-82925 decreased the summated ictal activity slightly
below one fifth of the control value, and its effects lasted
more than 180 min (see details earlier).
Possible blocking effect of VID-82925 on the GJal
communication
In treatment experiments, when VID-82925 was
administered first and after 100 min followed by carbe-
noxolone, no further depression of the summated ictal
activity was observed; neither was the duration of the
effect of VID-82925 modified in the presence of carbe-
noxolone (Fig. 3A). When carbenoxolone was applied
first and after 10 min followed by VID-82925, the
summated ictal activity was further decreased both in
intensity and duration in comparison to that when carbe-
noxolone was applied alone (Fig. 3B). The degree and
the duration of reduction of the summated ictal activity
in the presence of both carbenoxolone and VID-82925
Table 1. Effects of VID-82925 on the development of the epileptic focus
Time
(20 min window)
Number of seizures/20 min Duration of seizures (s) Amplitude (mV)
Control VID-82925 Trend Control VID-82925 Trend Control VID-82925 Trend
20 13 ± 3 9.1 ± 4 ﬂ3.9 16.9 ± 2 15.1 ± 4 ﬂ1.8 0.73 ± 0.1 0.59 ± 0.1 ﬂ0.14
40 12.4 ± 3 6.1 ± 2a ﬂ6.3 35.8 ± 7 29 ± 10 ﬂ6.8 0.85 ± 0.2 0.64 ± 0.1 ﬂ0.21
60 13.2 ± 4 4.9 ± 2a ﬂ8.3 36.6 ± 11 33.8 ± 11 ﬂ2.8 0.86 ± 0.2 0.69 ± 0.1 ﬂ0.17
80 12.8 ± 3 5.3 ± 1a ﬂ7.5 35.1 ± 9 31.4 ± 6 ﬂ3.7 0.95 ± 0.3 0.67 ± 0.1 ﬂ0.28
100 14.8 ± 4 5 ± 1a ﬂ9.8 34 ± 10 33 ± 9 ﬂ1 0.92 ± 0.3 0.71 ± 0.1 ﬂ0.21
120 14.2 ± 4 3.5 ± 1a ﬂ10.7 34.5 ± 11 39 ± 12 ›4.5 0.91 ± 0.4 0.74 ± 0.1 ﬂ0.17
140 15 ± 5 3.8 ± 1a ﬂ11.2 34.5 ± 9 39 ± 14 ›4.5 0.96 ± 0.2 0.75 ± 0.1 ﬂ0.21
160 15.5 ± 5 4 ± 1a ﬂ11.5 34 ± 12 40 ± 15 ›9.4 0.95 ± 0.2 0.76 ± 0.1 ﬂ0.19
180 15.7 ± 3 4.4 ± 1a ﬂ11.3 35.6 ± 9 45 ± 8 ›9.4 1 ± 0.2 0.77 ± 0.1 ﬂ0.23
200 15.9 ± 3 8.8 ± 2 ﬂ7.1 35.6 ± 8 47 ± 8a ›11.4 1 ± 0.1 0.82 ± 0.1 ﬂ0.18
220 15.7 ± 3 10 ± 2 ﬂ5.7 35.6 ± 8 48 ± 4a ›12.4 1 ± 0.2 0.83 ± 0.1 ﬂ0.17
The data illustrate the effects of VID-82925 on the number of seizures, on duration of seizures, and on the amplitude of epileptiform discharges in the pretreat-
ment experiments. Data are expressed as mean ± SD. Significance criterion: p < 0.05.
aSignificant changes.
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were very similar to that when VID-82925 was adminis-
tered alone.
Effects of VID-82925 on heart activity
In pretreatment experiments, the VID-82925 slightly
decreased the heart frequency, whereas the amplitudes of
QRS complex transiently decreased during the 60 min of
the pretreatment in comparison to control (Fig. 4A). Despite
these changes, both parameters remained in the physiologic
intervals and returned to the control level after the induction
of epileptiform activity. In treatment experiments, the ECG
did not show any considerable changes either in the heart
frequency or in the amplitudes of QRS complex in the pres-
ence of VID-82925 (Fig. 4B).
Discussion
The aim of the present study was to investigate the effects
of the ‘‘VID-82925’’ marked kinase inhibitor molecule both
on the development of the epileptic focus as well as on the
epileptiform activity of the already stable epileptic focus of
anaesthetised rats using the 4-AP–induced in vivo epilepsy
model. The data of VID-82925 were compared to those of
known AEDs and carbenoxolone.
Our results reveal that although the VID-82925 pretreat-
ment does not prevent completely the activation of an epi-
leptic focus, it suppresses significantly the manifestation of
the epileptiform activity not only during the developing
phase, but the epileptiform activity continues to remain at a
A
B
Figure 2.
Effects of pretreatment with VID-82925 (n = 10) or with levetiracetam (n = 5) (A) and treatment with VID-82925 (n = 10), or with
levetiracetam (n = 5), or with carbamazepine (n = 6) (B), respectively, on the seizure activity induced by 4-AP (considered as con-
trol). In A: Pretreatment means both the premanipulation of the cortex by the tested drug before 4-AP application (dotted panel) and
the manipulation of the cortex during the developing phase of the epileptic focus (light shaded panel). The stable phase of the focus is
represented by the dark shaded panel. In B: Treatment means the application of the drugs during the stable phase of the focus,
approximately 60 min after the application of 4-AP (see dark shaded panel in Fig. 2A). The ongoing treatment is indicated below each
vertical arrow. )20 on the time scale represents the last 20 min of the preceding 60-min seizure activity induced by 4-AP (considered
as control), just before the application of drugs. Data are expressed as mean ± SD. *Significant changes. Significance criterion:
p < 0.05.
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significantly depressed level for a considerable long time
even during the stable phase. Conversely, epileptiform
activity in the levetiracetam pretreated animals did not dif-
fer considerably from that of controls both during the devel-
oping phase and during the stable phase of the focus. From
these observations, we can conclude that VID-82925 does
have a suppressing effect on the development of the epilep-
tic focus, whereas levetiracetam does not have this kind of
Table 2. Effects of VID-82925 on the epileptiform activity of the already stable epileptic focus
Time
(20 min window)
Number of seizures/20 min Duration of seizures (s) Amplitude (mV)
Trend Trend Trend
Control 17.1 ± 4 38.3 ± 10 0.85 ± 0.1
VID-82925 20 14 ± 3 ﬂ3.1 24.6 ± 7 ﬂ13.7 0.79 ± 0.1 ﬂ0.06
VID-82925 40 11.8 ± 2a ﬂ5.3 24.5 ± 7a ﬂ13.8 0.80 ± 0.1 ﬂ0.05
VID-82925 60 11.3 ± 5a ﬂ5.8 23.3 ± 7a ﬂ15 0.79 ± 0.1 ﬂ0.06
VID-82925 80 10.4 ± 4a ﬂ6.7 24 ± 4a ﬂ14.3 0.78 ± 0.1 ﬂ0.07
VID-82925 100 6.8 ± 3a ﬂ10.3 23.3 ± 10a ﬂ15 0.80 ± 0.1 ﬂ0.05
VID-82925 120 6.4 ± 1 ﬂ10.7 24,4 ± 4a ﬂ13.9 0.81 ± 0.1 ﬂ0.04
VID-82925 140 5.3 ± 1a ﬂ11.8 21.9 ± 13 ﬂ16.4 0.81 ± 0.1 ﬂ0.04
VID-82925 160 5.3 ± 1a ﬂ11.8 26.1 ± 4a ﬂ12.2 0.83 ± 0.1 ﬂ0.02
VID-82925 180 4.7 ± 2a ﬂ12.4 26.5 ± 9a ﬂ11.8 0.82 ± 0.2 ﬂ0.03
VID-82925 200 4.9 ± 2a ﬂ12.2 27 ± 7a ﬂ11.3 0.81 ± 0.1 ﬂ0.04
VID-82925 220 5.3 ± 3a ﬂ11.8 28.2 ± 10 ﬂ10.1 0.79 ± 0.1 ﬂ0.06
VID-82925 240 7.4 ± 2a ﬂ9.7 37.8 ± 10 ﬂ0.5 0.86 ± 0.1 ›0.01
VID-82925 260 8.2 ± 4a ﬂ8.9 44.5 ± 10 ›6.2 0.87 ± 0.1 ›0.02
The data illustrate the effects of VID-82925 on the number of seizures, on duration of seizures and on the amplitude of epileptiform discharges in the treatment
experiments. Data are expressed as mean ± SD. Significance criterion: p < 0.05.
aSignificant changes.
Figure 3.
Effects of treatment with VID-82925
applied alone (n = 10) or together
with carbenoxolone (n = 10) (A)
and treatment with carbenoxolone
applied alone (n = 10) or together
with VID-82925 (n = 10) (B) on the
summated ictal activity. In A: In the
already epileptic animals, the VID-
82925 was administered first and
after 100 min carbenoxolone was
applied. In B: In the already epileptic
animals, the carbenoxolone was
applied first and after 10 min VID-
82925 was administered. The ongo-
ing treatment is indicated below
each vertical arrow. )20 on the
time scale represents the last
20 min of the preceding 60-min sei-
zure activity induced by 4-AP (con-
sidered as control), just before the
application of drugs. Data are
expressed as mean ± SD. *Signifi-
cant changes. Significance criterion:
p < 0.05.
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effect, although in treatment experiments levetiracetam sig-
nificantly reduced the epileptiform activity of the already
stable focus. Although previous experiments in the kindling
model suggested that levetiracetam in addition to its sei-
zure-suppressing activity may possess antiepileptogenic
activity (Lçscher et al., 1998), a recent study by Brandt
et al. (2007) in status epilepticus models revealed lack of an
antiepileptogenic effect of chronic treatment with leveti-
racetam. These discrepancies could be explained by the dif-
ferent conditions in the different models.
The long-lasting seizure depressing effect of VID-82925
might be the results of the persistent plastic changes induced
by VID-82925 in the cortical tissue early in the process of
epileptogenesis (both during the premanipulation of the
intact cortex and/or the manipulation of the cortex, during
the developing phase of the focus) that alter the subsequent
progressive evolution of the epilepsy. However, we cannot
exclude a possible treatment effect of the VID-82925 per-
sisting during the stable phase of the focus. These findings
further confirm our earlier suggestions that different cellular
and network mechanisms could be involved at least partially
in the development of the epileptic focus and in the mainte-
nance of seizure activity of an already stable epileptic focus.
The treatment of the animals with VID-82925 during the
stable phase of the epileptic focus turns out to be remarkably
effective against ictogenesis, indicated by significant reduc-
tions in both the numbers and durations of seizures as well
as by the considerably longer seizure free periods. The
power of the depressing effects of VID-82925 on the epilep-
tiform activity becomes obvious and worth considering if
we compare it to the efficacy of the already traded AEDs.
The antiepileptic activity of VID-82925 is at least as pro-
nounced as of the tested AEDs; however, the duration of its
effect is 2 or 3 times longer. Despite the noteworthy
depressing effects of VID-82925 on the epileptiform activ-
ity, it apparently does not influence the basic cortical elec-
tric activity of the rats and does not exert any serious
harmful effect on their heart activity.
Currently there are about 20 different AEDs available on
the market and some compounds in various stages of clini-
cal phases (Rogawski, 2006), but none of them are reported
to aim at the modulation of the action of protein kinases.
These enzymes have major roles in signal transduction path-
ways with broad substrate specificity, indicating their
involvement in many cellular events, both physiologic and
pathologic, including epilepsy. It has been shown that
increased activity of different kinases can contribute to the
dysfunction of both ion (Bernard et al., 2004) and neuro-
transmitter receptor channels (Tehrani & Barnes, 1995;
Rakhade et al., 2008) that are involved in several types of
Figure 4.
Effects of pretreatment (A) and
treatment (B) with VID-82925 on
the heart frequency and on the
amplitudes of QRS complex. Data
are expressed as mean ± SD.
Significance criterion: p < 0.05.
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epilepsy. Inhibition of several kinases has also been
reported to reduce seizure activity (Weisner et al., 1999;
Inan & Bykafsar, 2008; Queiroz & Mello, 2008) and to
have antiepileptogenic properties in genetic epilepsy (Zeng
et al., 2009).
Several reports confirm that phosphorylations can also
regulate GJal communication at multiple levels. Protein kin-
ases are involved not only in several points of the lifecycle
of the GJ channels [starting from the gene expression of the
GJ channel forming proteins (connexin, Cx) through the
trafficking of Cxs and their assembly into functioning chan-
nels as well as their disassembly and degradation] but also
in the gating of GJ channels (Cruciani & Mikalsen, 2002;
Laird, 2005; Moreno& Lau, 2007). Phosphorylation is dem-
onstrated to modify the permselectivity of the GJ channels
formed by different Cxs to specific signaling molecules
(Goldberg et al., 2002). It has been reported that both neuro-
nal and glial Cxs have sites for phosphorylation for a num-
ber of protein kinases (Lampe & Lau, 2004). Most of the
data available are related to Cx43 (astrocyte specific Cx),
showing that activation of protein kinase A, protein kinase
C, p34(cdc2)/cyclin B kinase, casein kinase 1, mitogen-
activated protein kinase, and pp60(src) kinase can lead to
phosphorylation of the majority of the 21 serine and 2 of the
tyrosine residues in the C-terminal region of Cx43 (Lampe
& Lau, 2004).
Our results indicate that in the presence of VID-82925,
the GJ channel blocker carbenoxolone does not exert addi-
tional depressing effect on the epileptiform activity. Carbe-
noxolone is known to reduce effectively the seizure activity
in different epilepsy models both in vitro (Jahromi et al.,
2002; Gigout et al., 2006) and in vivo (Szente et al., 2002;
Gajda et al., 2006; Nilsen et al., 2006; Medina-Ceja et al.,
2008). This may be the indication that VID-82925 and car-
benoxolone are in competition at least partially on influenc-
ing GJal communication. Because VID-82925 is able to
exert additional depressing effect on the epileptiform activ-
ity in both intensity and duration in the presence of carbe-
noxolone, it seems possible that VID-82925 has more
complex effects on seizure activity than just blocking of
GJal communication. The VID-82925 influenced the dura-
tion of seizures and the amplitudes of seizure discharges dif-
ferently depending on the actual phase of the focus. These
observations indicate that VID-82925 might affect partially
distinct mechanisms during the development of an epileptic
focus and during the activity of an already stable focus.
Our results suggest that VID-82925 might provide novel
strategy for epilepsy treatment that might be effective not
only for the currently drug-resistant epilepsies, but also for
suppressing the development of a stable epileptic focus tar-
geting primary cell signaling pathways that trigger the
downstream mechanisms underlying epileptogenesis.
Because the VID-82925 was administered intravenously, its
remarkable antiepileptic effects suggest that the compound
crosses the blood–brain barrier successfully, an essential
feature of a potential antiepileptic drug. However, more
exact molecular biologic investigation must be carried out
to identify the entire cellular targets of VID-82925, and
detailed pharmacokinetic, pharmacodynamic, and toxicoki-
netic analysis are needed, but these investigations are
beyond of the scope of the present study.
Considering the complex role of various protein kinases
in cellular signaling pathways, it seems likely that modula-
tion of their activities might open new possibilities for
epilepsy prophylaxis and therapy.
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